@article{9bfc354db8bb4e2a91acdc559239183d,
title = "Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program",
abstract = "MLN0128 is an investigational small molecule ATP-competitive inhibitor of the serine/threonine kinase mTOR. MLN0128 was tested against the in vitro panel at concentrations ranging from 0.1nM to 1μM and against the PPTP in vivo panels at a dose of 1mg/kg administered orally daily×28. In vitro the median relative IC50 concentration was 19nM. In vivo MLN0128 induced significant differences in EFS in 24/31 (77\%) solid tumor models, but 0/7 ALL xenografts. The modest activity observed for MLN0128 against the PPTP preclinical models is similar to that previously reported for another TOR kinase inhibitor.",
keywords = "Developmental therapeutics, MTOR inhibitor, Preclinical testing",
author = "Kang, \{Min H.\} and Reynolds, \{C. Patrick\} and Maris, \{John M.\} and Richard Gorlick and Kolb, \{E. Anders\} and Richard Lock and Hernan Carol and Keir, \{Stephen T.\} and Jianrong Wu and Dmitry Lyalin and Kurmasheva, \{Raushan T.\} and Houghton, \{Peter J.\} and Smith, \{Malcolm A.\}",
year = "2014",
month = aug,
doi = "10.1002/pbc.24989",
language = "English",
volume = "61",
pages = "1486--1489",
number = "8",
}